This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Haussmann, H.-J. Search for Related Content PubMed PubMed Citation Articles by Haussmann, H.-J. Social Bookmarking                         What's this?

Smoking and Lung Cancer: Future Research Directions

Toxicology Consultant, Roesrath, Germany

Correspondence: Address correspondence to Hans-Juergen Haussmann, Ueberhoefer Feld 36a, 51503 Roesrath, Germany. E-mail:HansJ.Haussmann{at}T-Online.de

The aim of future research in this area is to provide the mechanistic understanding and the tools for effective prevention, early diagnosis, and therapy of lung cancer. With the established causal link between cigarette smoking and the risk of developing lung cancer, the most effective prevention is certainly not to smoke. A much better mechanistic understanding of lung cancer and its variability will support the development and evaluation of potentially reduced risk products for those who maintain smoking as well as for the development of early diagnostic tools and targeted therapies. Because of the complexity of lung cancer and the long duration for its development, nonclinical and clinical research efforts need to complement each other. Recent promising advances in this research area are the understanding of the interaction between genotoxic and epigenetic effects of smoking, the development of laboratory animal models for lung tumorigenesis by smoke inhalation, the unraveling of molecular pathways and signatures in clinical lung cancer research useful for developing diagnostic tools and therapeutic approaches, and the first successful therapy for lung cancer—although less suitable for smokers. The above—in combination with emerging data sets from explorative non-clinical and clinical studies as well as improved modeling approaches—are setting the stage for accelerated progress towards developing successful early diagnostic tools and therapies as well as for the assessment of new consumer products with potentially reduced risk.

Key Words: Animal Models • Clinical Biomarkers • DNA Promoter Methylation • Lung Cancer • Molecular Mechanisms • Tobacco Harm Reduction

International Journal of Toxicology, Vol. 26, No. 4, 353-364 (2007)
DOI: 10.1080/10915810701490463


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				V. T. Vasu, C. E. Cross, and K. Gohil Nr1d1, an Important Circadian Pathway Regulatory Gene, Is Suppressed By Cigarette Smoke in Murine Lungs Integr Cancer Ther, December 1, 2009; 8(4): 321 - 328. [Abstract] [PDF]

				R. E Tremblay Understanding development and prevention of chronic physical aggression: towards experimental epigenetic studies Phil Trans R Soc B, August 12, 2008; 363(1503): 2613 - 2622. [Abstract] [Full Text] [PDF]